Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
17 February 2005
Following a European-wide review of the cardiovascular data, the evidence suggests that selective COX-2 inhibitors, as a class, may cause an increased risk of thrombotic events (for example, myocardial infarction and stroke) compared with placebo and some NSAIDs, and the risk may increase with dose and duration of exposure.
› Letter to healthcare professionals (incorporating a question and answer document)
Updated advice on the safety of selective cox-2 inhibitors. 
